<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrea T Cruz, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1060361588"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nontuberculous mycobacteria (NTM) are a miscellaneous collection of acid-fast bacteria that are widespread in the environment [<a href="#rid1">1</a>]. They have been isolated from numerous environmental sources including water, soil, food products, and domestic and wild animals [<a href="#rid2">2</a>]. Health care-associated transmission has occurred with medical equipment [<a href="#rid3">3-5</a>].</p><p>This topic will provide an overview of NTM disseminated infections and bacteremia in children. NTM lymphadenitis, SSTI, and pulmonary infections in children are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86045.html" rel="external">"Nontuberculous mycobacterial lymphadenitis in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/85895.html" rel="external">"Nontuberculous mycobacterial skin and soft tissue infections in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/85894.html" rel="external">"Nontuberculous mycobacterial pulmonary infections in children"</a>.)</p><p></p><p class="headingAnchor" id="H22091078"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>More than 170 species of have been identified, not all of which have been documented to cause disease in humans [<a href="#rid6">6-9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – NTM pathogens are classified as rapidly growing or slowly growing (<a class="graphic graphic_table graphicRef61936" href="/z/d/graphic/61936.html" rel="external">table 1</a>). Rapidly growing species grow within seven days and include <em>Mycobacterium fortuitum</em>, <em>Mycobacterium abscessus</em>, and <em>Mycobacterium chelonae</em>. Slowly growing species require several weeks to grow and include <em>Mycobacterium avium </em>complex (MAC),<em> Mycobacterium marinum</em>, and<em> Mycobacterium kansasii</em>. (See  <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria", section on 'Classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease associations</strong> – NTM can cause a broad range of infections that vary depending on the particular NTM species and the host. In children, NTM cause four main clinical syndromes: lymphadenopathy, skin and soft tissue infection (SSTI), pulmonary disease (predominantly in children with underlying pulmonary conditions), and disseminated disease (predominantly in children with immune compromise).</p><p></p><p class="bulletIndent1"><em>M. avium</em> complex (MAC) is the most common cause of disseminated NTM infection in children without central vascular access [<a href="#rid10">10,11</a>]. In children with indwelling vascular catheters, <em>Mycobacterium mucogenicum</em> and other species that are ubiquitous in water supplies have been reported [<a href="#rid12">12-15</a>].</p><p></p><p>The microbiology, culture requirements, and methods of speciation for NTM are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria"</a>.)</p><p class="headingAnchor" id="H22091092"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Estimates of the true burden of NTM infections in children are unavailable; in part because NTM infections may be asymptomatic and because NTM infections are not communicable, reporting of NTM infections is not required in the United States or many other countries [<a href="#rid2">2</a>]. Nonetheless, the overall prevalence of NTM disease appears to be increasing with time (possibly as a result of enhanced detection) [<a href="#rid16">16-20</a>]. One study estimated that disseminated NTM was seen in 3.7 per 100,000 inpatients [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a>.)</p><p>Disseminated NTM is rare in immune-competent children. In a prospective surveillance study, only 3 of 192 children with confirmed or probable NTM infection had disseminated disease [<a href="#rid22">22</a>]. Two of the cases occurred in immunocompromised children with intravenous catheter-related bacteremia. Most case series of disseminated NTM describe disseminated <em>M. avium </em>complex (MAC) in children with acquired immunodeficiency virus [<a href="#rid23">23,24</a>]. However, with the advent of potent antiretroviral therapy, the incidence of disseminated MAC in HIV-positive children has declined [<a href="#rid11">11,25,26</a>]. One study estimated that disseminated NTM was seen in 3.7 per 100,000 inpatients [<a href="#rid21">21</a>].</p><p>NTM are transmitted through environmental sources. Water (from both natural and treated sources) is a common reservoir [<a href="#rid12">12-14,27-31</a>]. Aquatic transmission of NTM is facilitated by the formation of biofilms, which permit survival under a variety of environmental conditions and, through detachment, allow dissemination of large numbers of organisms [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/5345.html" rel="external">"Pathogenesis of nontuberculous mycobacterial infections"</a>.)</p><p>The respiratory and gastrointestinal tracts are the usual portal of entry for disseminated disease. However, direct inoculation may occur. NTM bacteremia in pediatric oncology patients has been reported after flushing central lines with tap water and when inadequate chlorination allowed proliferation of NTM species in water from hospital faucets [<a href="#rid12">12-14</a>].</p><p>The incubation periods are variable [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H1060363832"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Cases of nontuberculous mycobacteria (NTM) bacteremia or disseminated NTM disease in children have been reported among children with:</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital defects in interferon-gamma and interleukin (IL)-12 synthesis and response pathways, including signal transducer and activator of transcription 1 (<em>STAT1</em>) mutations, and <em>GATA2</em> mutations, which can be associated with <em>M. avian complex</em> infections and monocytopenia [<a href="#rid33">33-40</a>] (see  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects"</a>)</p><p></p><p class="bulletIndent1">In a retrospective study in HIV-infected adults, disseminated NTM disease was associated with interferon-gamma neutralizing autoantibodies, a risk factor for disseminated NTM disease that is less well appreciated than congenital defects in interferon-gamma synthesis and response pathways [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">While children with severe combined immunodeficiency, DiGeorge syndrome, chronic granulomatous disease, and hyperimmunoglobulin M syndrome also have defects in portions of the IL-12 pathway, they are not prone to disseminated infection with NTM species [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy for malignancy [<a href="#rid43">43,44</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Solid organ (particularly organs other than the lungs) or hematopoietic cell transplantation [<a href="#rid43">43,45-48</a>] (see  <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous catheter (particularly in immune-compromised patients) [<a href="#rid10">10,15,22,44,49</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advanced HIV infection [<a href="#rid11">11,23,24</a>] (see  <a class="medical medical_review" href="/z/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV"</a>)</p><p></p><p class="headingAnchor" id="H564807774"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Disseminated NTM disease occurs almost exclusively in immune-compromised children. Clinical features are nonspecific and may include fever, weight loss, sweating, diarrhea, generalized lymphadenopathy, generalized cutaneous lesions (<a class="graphic graphic_picture graphicRef86162" href="/z/d/graphic/86162.html" rel="external">picture 1</a>), diffuse abdominal tenderness, and hepatosplenomegaly [<a href="#rid24">24,25,46,50-53</a>].</p><p>Symptoms and signs reflect the major sites of involvement (eg, bone marrow, lymphoreticular system, gastrointestinal tract, lungs). Skin lesions may be the first manifestation of disseminated infection [<a href="#rid54">54</a>]. Patients with HIV infection who have recently initiated antiretroviral therapy may present with immune reconstitution inflammatory syndrome. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> below.)</p><p>There is little information about the presenting signs of disseminated NTM in children. However, in one series of 20 HIV-positive children with disseminated <em>M. avium </em>complex (MAC), all 20 had persistent failure to gain weight, 18 had anorexia, 18 had abdominal pain/tenderness, and 16 had persistent or recurrent fever [<a href="#rid24">24</a>]. Fourteen had all four symptoms, and six patients had at least two of the four symptoms. Nine had intermittent diarrhea, three had persistent diarrhea, five had night sweats, and three had joint pain.</p><p class="headingAnchor" id="H1060365934"><span class="h1">LABORATORY FEATURES</span><span class="headingEndMark"> — </span>Laboratory findings of disseminated NTM disease are nonspecific and may include normocytic anemia, elevated lactate dehydrogenase, and elevated alkaline phosphatase [<a href="#rid25">25,55</a>]. Bacteremia may be intermittent and low grade [<a href="#rid50">50,52,56,57</a>].</p><p class="headingAnchor" id="H22091180"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Disseminated NTM disease should be suspected in immune-compromised children with skin lesions or nonspecific symptoms and signs (eg, weight loss, abdominal pain, fever, etc) without other plausible explanations.</p><p>Definitive diagnosis disease requires recovery of NTM from blood, bone marrow, liver, visceral lymph nodes, or other normally sterile body site [<a href="#rid54">54,58,59</a>]. Culture is essential to differentiate NTM from <em>Mycobacterium</em> <em>tuberculosis</em>, determine which species of NTM is causing infection, and perform drug-susceptibility testing [<a href="#rid53">53</a>].</p><p>More than 90 percent of individuals diagnosed with disseminated <em>M. avium</em> complex (MAC) have positive blood cultures [<a href="#rid50">50</a>]. Multiple blood cultures may be required because NTM bacteremia can be intermittent and low grade [<a href="#rid52">52,56,57,60</a>]. Mycobacterial blood cultures are collected in special media, different from the media used in standard bacterial blood cultures, and must be specifically requested. (See  <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria", section on 'Culture'</a>.)</p><p>Although optimal therapy for NTM generally requires identification at the species level, <em>M. abscessus</em> should be identified at the subspecies level. Two of the three subspecies of <em>M. abscessus</em> (subspecies <em>abscessus</em> and subspecies <em>bolletii</em>) have inducible macrolide resistance, whereas <em>M. abscessus</em> subspecies <em>massiliense</em> is macrolide susceptible and is associated with greater treatment success [<a href="#rid61">61</a>]. Identification of children likely to benefit from macrolide therapy is particularly important for <em>M. abscessus</em>, given the limited number of well-tolerated therapy options. (See <a class="local">'Antimycobacterial therapy'</a> below.)</p><p>In patients with suspected disseminated NTM and two negative blood cultures, diagnosis of disseminated NTM disease may require tissue specimens from involved sites (eg, bone marrow, liver, lymph node) for culture, acid-fast stains, and histopathology [<a href="#rid50">50</a>]. Intrathoracic, intra-abdominal, or retroperitoneal adenopathy may be accessible through fine-needle aspiration.</p><p>Ophthalmologic examination demonstrating granulomatous choroidal lesions or uveitis supports a diagnosis of disseminated NTM disease [<a href="#rid62">62</a>] but cannot differentiate disseminated NTM disease from miliary tuberculosis or tuberculous meningitis.</p><p>Histopathology demonstrating acid-fast bacilli (AFB) or granulomas supports the diagnosis of disseminated NTM disease in children with negative blood cultures. However, these findings do not distinguish NTM from <em>M. tuberculosis</em>, and the absence of these findings does not exclude NTM disease. In one series of immune-compromised (non-HIV) adults with disseminated NTM infection, only one-half had biopsy findings consistent with mycobacterial infection (eg, granulomas), and AFB smears were positive in fewer than 20 percent [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H1590631880"><span class="h1">POSTDIAGNOSIS EVALUATION</span><span class="headingEndMark"> — </span>NTM bacteremia in immunocompromised children should prompt evaluation for disease at remote sites; this may include computed tomography of the chest, abdomen, and pelvis. In a small series of pediatric oncology patients, four of five children with vascular catheter-associated NTM bacteremia had pulmonary nodules [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H22091215"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of disseminated nontuberculous mycobacterial disease in immune-compromised children includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated fungal disease (see  <a class="medical medical_review" href="/z/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nocardiosis (see  <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">"Nocardia infections: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Actinomycosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Miliary tuberculosis (see  <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metastatic disease (in older patients)</p><p></p><p>Histopathology and/or microbiology studies are needed to differentiate among the possible etiologies.</p><p class="headingAnchor" id="H564807864"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1590632016"><span class="h2">General measures</span></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of disseminated NTM in immune-compromised children should be undertaken in consultation with an expert in infectious diseases [<a href="#rid9">9,50,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If bacteremia or disseminated infection is associated with a vascular catheter, the catheter must be removed. It is rare to clear NTM bacteremia with the line in situ [<a href="#rid15">15,64</a>].</p><p></p><p class="bulletIndent1">There are reports of isolated cases of NTM bacteremia being successfully treated with removal of the vascular catheter without antimycobacterial therapy [<a href="#rid14">14</a>]. However, given the potential for development of pulmonary nodules or other signs of disseminated disease in asymptomatic immunocompromised children [<a href="#rid43">43</a>], we suggest antimycobacterial therapy in addition to removal of the catheter.</p><p></p><p class="headingAnchor" id="H1590632073"><span class="h2">Antimycobacterial therapy</span><span class="headingEndMark"> — </span>Treatment for disseminated NTM infection or bacteremia is usually divided into two phases. The initial phase is more intensive and usually based upon the most likely susceptibility patterns. The continuation phase is less intensive and may be tailored according to susceptibilities, if susceptibilities are available.</p><p class="headingAnchor" id="H1845298317"><span class="h3">Antimicrobial susceptibility</span><span class="headingEndMark"> — </span><em>M. avium</em> complex (MAC) is the most common NTM species associated with disseminated NTM disease in children. MAC is generally susceptible to macrolide antibiotics with good correlation between in vitro testing and clinical response [<a href="#rid50">50</a>].</p><p><em>M. mucogenicum</em> is another potential cause of disseminated NTM among children with indwelling vascular catheters [<a href="#rid12">12-14</a>]. In vitro, <em>M. mucogenicum</em> is usually susceptible to macrolides, carbapenems, fluoroquinolones, <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX), and aminoglycosides [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H1590633266"><span class="h3">Initial phase</span><span class="headingEndMark"> — </span>The initial phase of antimycobacterial for disseminated NTM infection or bacteremia is more intensive and usually based upon the most likely susceptibility patterns of the isolate.</p><p>For children with disseminated NTM disease or NTM bacteremia, we suggest therapy with <strong>at least three</strong> drugs to which the isolate is susceptible (or likely susceptible if susceptibility studies are pending) for the first one to two months or until clinical and/or radiographic improvement is noted. A typical regimen may include (<a class="graphic graphic_table graphicRef86161" href="/z/d/graphic/86161.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A macrolide (<a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a> or <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13286" href="/z/d/drug information/13286.html" rel="external">Ethambutol</a></p><p class="bulletIndent1"><span class="glyph">●</span>A rifamycin (<a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> or <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">rifabutin</a>)</p><p></p><p><a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">Amikacin</a>, <a class="drug drug_pediatric" data-topicid="12807" href="/z/d/drug information/12807.html" rel="external">streptomycin</a>, or a fluoroquinolone may be substituted for the macrolide or added as a fourth drug for patients who develop breakthrough MAC while receiving MAC prophylaxis or for patients in whom there is concern about macrolide resistance [<a href="#rid50">50</a>].</p><p>There are no randomized controlled trials evaluating therapy for disseminated NTM in children. In randomized and observational studies in adults with HIV and disseminated MAC, multidrug regimens that include macrolides have been associated with clinical and microbiologic improvement [<a href="#rid65">65-67</a>]. Monotherapy with <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a> reduced bacteremia, but nearly one-half of patients developed clarithromycin resistance, so monotherapy is contraindicated [<a href="#rid68">68</a>]. The addition of rifamycin to multidrug regimens that do not include macrolides is associated with shorter duration of bacteremia [<a href="#rid69">69</a>]. Although this benefit is not clear in macrolide-containing multidrug regimens, the addition of rifamycin appears to be associated with decreased development of macrolide-resistance [<a href="#rid66">66,67</a>]. This is likely due to rifamycins killing subpopulations that are macrolide resistant and macrolides killing subpopulations that are rifamycin resistant.</p><p>We generally prefer <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a> to <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a> as the macrolide agent for patients with disseminated NTM infection. Although early studies of macrolides for NTM were conducted with clarithromycin, azithromycin may be preferable for at least two reasons. First, it can be administered once daily, which may increase adherence. Second, there is a potential for drug interaction between clarithromycin and rifamycins. In observational studies, coadministration of clarithromycin and rifamycin decreased serum concentrations of clarithromycin [<a href="#rid70">70,71</a>]. In many cases, the concentration was lower than the minimum inhibitory concentration (MIC) of the organism, which may lead to acquired antibiotic resistance [<a href="#rid70">70</a>]. Clarithromycin also appears to induce greater <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">erythromycin</a> ribosome methyltransferase gene (<em>erm</em>) expression and higher macrolide resistance than azithromycin for <em>M. abscessus</em> [<a href="#rid72">72</a>]. It is unclear the degree to which the benefit of combination therapy outweighs the risk of selecting for clarithromycin resistance. However, using azithromycin rather than clarithromycin permits combination therapy without potentially sacrificing the MIC.</p><p class="headingAnchor" id="H1845298724"><span class="h3">Continuation phase</span><span class="headingEndMark"> — </span>The continuation phase of antimycobacterial therapy is less intensive than the initial phase. The continuation phase usually begins after one to two months, when the child has demonstrated clinical improvement. The child is transitioned to two drugs, based upon the results of susceptibility studies. If possible, the two-drug regimen should be entirely oral.</p><p class="headingAnchor" id="H1590632894"><span class="h3">Duration</span><span class="headingEndMark"> — </span>The total duration of therapy usually is 6 to 12 months [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H1590632935"><span class="h2">Monitoring adverse effects</span></p><p class="headingAnchor" id="H1590633258"><span class="h3">Drug-specific effects</span><span class="headingEndMark"> — </span>The antimycobacterial agents that are used to treat disseminated NTM infections and NTM bacteremia often are difficult to tolerate, and some have important toxicities (<a class="graphic graphic_table graphicRef86161" href="/z/d/graphic/86161.html" rel="external">table 2</a>). It may be challenging to determine which of the multiple medications is responsible for a given reaction. In addition, children with comorbid medical conditions may require additional medications that can interact with antimycobacterial therapy, particularly with rifamycins [<a href="#rid17">17</a>]. They also may have baseline hepatic or renal dysfunction, which may decrease medication tolerance.</p><p>Although most adverse effects are monitored clinically by assessing the patient for symptoms (eg, dizziness, vomiting), some specific parameters should be monitored at baseline or periodically as indicated below, even in children without comorbid medical conditions [<a href="#rid50">50</a>].</p><p>For children receiving combination <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> (rifampicin), <a class="drug drug_pediatric" data-topicid="13286" href="/z/d/drug information/13286.html" rel="external">ethambutol</a>, and macrolide therapy (with or without other agents), we suggest baseline complete blood count (CBC), electrocardiogram (ECG), alkaline phosphatase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT). Thereafter, the need for subsequent laboratory evaluation should be driven by symptoms and/or examination findings; scheduled laboratory evaluation may not be needed unless patients are receiving other marrow-suppressive or potentially hepatotoxic medications. If the regimen includes other agent(s), the specific parameters for those agents should be monitored as indicated below. Ethambutol is rapidly metabolized in children and ocular toxicity is extremely rare in children with normal renal function [<a href="#rid73">73,74</a>]. For the treatment of <em>M. tuberculosis</em> in children, the World Health Organization recommends vision screening if possible, but unavailability of vision screening is not a contraindication to using ethambutol [<a href="#rid75">75</a>].</p><p>For children receiving other regimens, we suggest baseline CBC, alkaline phosphatase, AST, and ALT followed by periodic monitoring of specific parameters for particular agents as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Rifamycins (<a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a>, <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">rifabutin</a>, <a class="drug drug_pediatric" data-topicid="110542" href="/z/d/drug information/110542.html" rel="external">rifapentine</a>) – Periodic CBC to evaluate granulocytopenia and thrombocytopenia (see  <a class="medical medical_review" href="/z/d/html/491.html" rel="external">"Rifamycins (rifampin, rifabutin, rifapentine)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Macrolides (eg, <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a>, <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a>) – Baseline ECG before initiation of therapy to evaluate prolongation of the QT interval; periodic alkaline phosphatase, AST, and ALT during the first three months of therapy to evaluate hepatotoxicity (see  <a class="medical medical_review" href="/z/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'Adverse reactions'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13393" href="/z/d/drug information/13393.html" rel="external">Isoniazid</a> – Periodic monitoring of AST and ALT may be warranted in children with pulmonary NTM who are at increased risk for liver disease (eg, those with cystic fibrosis) or are receiving other medications that are metabolized in the liver (see  <a class="medical medical_review" href="/z/d/html/477.html" rel="external">"Isoniazid hepatotoxicity"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aminoglycosides (including <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a> and <a class="drug drug_pediatric" data-topicid="12807" href="/z/d/drug information/12807.html" rel="external">streptomycin</a>) – Periodic hearing evaluations and renal function tests to monitor ototoxicity (both sensorineural hearing loss and vestibulitis) and nephrotoxicity; for children receiving amikacin, periodic amikacin levels</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13131" href="/z/d/drug information/13131.html" rel="external">Cefoxitin</a> – Periodic CBC to monitor bone marrow suppression</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TMP-SMX – Periodic CBC to monitor bone marrow suppression</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">Linezolid</a> – Periodic CBC to monitor bone marrow suppression; periodic eye examinations by an ophthalmologist to evaluate optic neuritis</p><p></p><p class="headingAnchor" id="H1590633237"><span class="h3">Immune reconstitution inflammatory syndrome</span><span class="headingEndMark"> — </span>Immune reconstitution inflammatory syndrome (IRIS) refers to clinical worsening while receiving effective antimycobacterial chemotherapy and is well described in HIV-infected patients [<a href="#rid76">76</a>]. IRIS can result in worsening of existing symptoms (paradoxical IRIS) or new onset of opportunistic infections after immune reconstitution (unmasking IRIS). The most common symptoms of NTM IRIS include fever, abdominal pain, subcutaneous nodules, and suppurative lymphadenitis.</p><p>One series reported NTM-induced IRIS in 9 (5 percent) of 153 HIV-infected children 2 to 26 weeks after initiation of ART; MAC and <em>Mycobacterium</em> <em>scrofulaceum</em> were the most common isolates [<a href="#rid77">77</a>]. Another pediatric series documented IRIS from a number of causes, mycobacterial and otherwise, in up to 20 percent of HIV-infected children initiating ART; IRIS was associated with malnutrition and high viral loads [<a href="#rid78">78</a>].</p><p>Although IRIS has been associated with death (primarily from rapidly enlarging lymph nodes causing airway compression or expansile central nervous system lesions causing brainstem herniation), most IRIS cases are mild and can be managed with nonsteroidal anti-inflammatory medications or glucocorticoids [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p class="headingAnchor" id="H1326137755"><span class="h2">Response to therapy</span><span class="headingEndMark"> — </span>Most patients who are treated for disseminated NTM infection have improvement in fever after two to four weeks and improvement in symptoms after four to six weeks of initial therapy [<a href="#rid79">79</a>]. However, clinical improvement may be delayed in patients with extensive disease or advanced immunosuppression. Patients who do not have clinical improvement after four to eight weeks of initial therapy should have NTM blood culture repeated. Clearance of NTM from the blood may take up to 12 weeks.</p><p class="headingAnchor" id="H1845299856"><span class="h2">Treatment failure</span><span class="headingEndMark"> — </span>Treatment failure is defined by the absence of a clinical response and persistence of mycobacteremia after 8 to 12 weeks of treatment [<a href="#rid53">53</a>].</p><p>For children with treatment failure, susceptibility testing should be repeated on the NTM isolate and a new treatment regimen instituted [<a href="#rid53">53</a>]. This regimen should be determined in consultation with an expert. It should include at least two drugs to which the isolate is susceptible and were not previously used (eg, <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a>, quinolones, <a class="drug drug_pediatric" data-topicid="12807" href="/z/d/drug information/12807.html" rel="external">streptomycin</a>). In a small case series, interferon alpha therapy was associated with clinical and microbiologic improvement in children with interferon-gamma receptor mutations who failed to respond to initial therapy [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'IFN-gamma receptor deficiencies'</a>.)</p><p class="headingAnchor" id="H22091280"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H1060354087"><span class="h2">HIV-positive children</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation of MAC primary prophylaxis</strong> – Primary prevention against <em>M. avium</em> complex (MAC) should be offered to for HIV-infected children with low CD4 cell counts [<a href="#rid53">53</a>]. Given the variation in normal CD4 cell count by age and that disseminated MAC has been seen in young children with high CD4 cell counts, prophylaxis should be offered to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children &lt;1 year: &lt;750 cells/microL</p><p class="bulletIndent2"><span class="glyph">•</span>Children 1 to &lt;2 years: &lt;500 cells/microL</p><p class="bulletIndent2"><span class="glyph">•</span>Children 2 to 5 years: &lt;75 cells/microL</p><p class="bulletIndent2"><span class="glyph">•</span>Children ≥6 years: &lt;50 cells/microL</p><p></p><p class="bulletIndent1">Before initiation of prophylaxis, a blood culture should be performed to exclude disseminated MAC [<a href="#rid50">50,53</a>]. Primary prophylaxis usually consists of a macrolide, either:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">Azithromycin</a> 20 mg/kg (maximum dose 1200 mg) orally weekly, <strong>or</strong></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">Clarithromycin</a> 7.5 mg/kg (maximum dose 500 mg) orally twice daily</p><p></p><p class="bulletIndent1">For patients unable to tolerate macrolides, <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">rifabutin</a> (300 mg orally once daily with food for children older than five years) is a less effective alternative [<a href="#rid81">81,82</a>]. However, it should not be used until <em>M. tuberculosis</em> disease has been excluded (because monotherapy with rifabutin could lead to resistance). <em>M. tuberculosis</em> should be excluded by <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (or interferon-gamma release assays in children ≥2years of age [<a href="#rid83">83</a>]), assessment of <em>M. tuberculosis</em> risk factors, and, for children with acid-fast bacillus-smear positive respiratory specimens, polymerase chain reaction for <em>M. tuberculosis</em>. (See  <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1">In randomized controlled trials in HIV-positive adults with decreased CD4 counts, the incidence of MAC bacteremia was reduced in patients who received MAC prophylaxis with <a class="drug drug_pediatric" data-topicid="12766" href="/z/d/drug information/12766.html" rel="external">rifabutin</a> [<a href="#rid84">84</a>]; subsequent trials comparing macrolides and rifabutin found macrolides to be superior [<a href="#rid81">81,82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinuation of MAC primary prophylaxis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children &lt;2 years of age</strong> – Discontinuation of prophylaxis is not recommended for children younger than two years of age [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children ≥2 years of age</strong> – For children ≥2 years of age who have received ≥6 months of antiretroviral therapy, primary MAC prophylaxis can be discontinued if they have had high CD4+ cell counts for ≥3 consecutive months; high CD4+ cell counts are defined according to age as follows [<a href="#rid53">53</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age 2 through 5 years: ≥200 cells/microL</p><p class="bulletIndent3"><span class="glyph">-</span>Age ≥6 years: ≥100 cells/microL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reinitiation of MAC primary prophylaxis </strong>– For children who have less optimal virologic control and a subsequent decline in CD4+ cell count, MAC primary prophylaxis should be restarted if: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CD4+ cell count is &lt;200 cells/microL for children 2 through 5 years of age</p><p class="bulletIndent2"><span class="glyph">•</span>CD4+ cell count is &lt;100 cells/microL for children ≥6 years of age</p><p></p><p class="headingAnchor" id="H1060354137"><span class="h2">Other immune-compromised hosts</span><span class="headingEndMark"> — </span>Whether immune-compromised children who do not have HIV infection should receive prophylaxis for MAC depends upon the underlying disorder.</p><p></p><p>Given the low incidence of MAC in pediatric hematopoietic stem cell transplantation recipients [<a href="#rid85">85</a>], prophylaxis is not routinely recommended.</p><p>Use of macrolide prophylaxis after lung transplantation is controversial. There is evidence that long-term macrolide usage decreases intracellular killing of mycobacteria within macrophages [<a href="#rid79">79</a>]. However, preexisting <em>M. abscessus</em> lung disease in cystic fibrosis patients has been associated with disease recurrence posttransplantation [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H22091287"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>The morbidity and mortality for disseminated NTM disease is substantial [<a href="#rid24">24</a>]. The outcome often is related to immune system recovery (eg, initiation of antiretroviral therapy [ART] in HIV-infected children or reduction of immunosuppressive regimen in organ transplant recipients).</p><p>After the advent of potent ART, the incidence of disseminated NTM infection among children in the Perinatal AIDS Collaborative Transmission Study declined from 1.3 to 0.2 cases per 100 patient years [<a href="#rid11">11</a>]. Fewer opportunistic infections were associated with increased survival.</p><p class="headingAnchor" id="H1389383448"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113062.html" rel="external">"Society guideline links: Nontuberculous mycobacteria"</a>.)</p><p class="headingAnchor" id="H22091294"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong> – Disseminated nontuberculous mycobacterial (NTM) disease and NTM bacteremia occur in children with congenital or acquired immunodeficiency. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> –<em> Mycobacterium avium</em> complex (MAC) is the most common cause of disseminated NTM infection in children without central vascular access. Among children with central vascular access, <em>Mycobacterium</em> <em>mucogenicum </em>and other species that are ubiquitous in water supplies have been reported. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical and laboratory features</strong> – Clinical and laboratory features are nonspecific and may include fever, weight loss/failure to gain weight, night sweats, generalized lymphadenopathy, skin lesions (<a class="graphic graphic_picture graphicRef86162" href="/z/d/graphic/86162.html" rel="external">picture 1</a>), abdominal tenderness, diarrhea, hepatosplenomegaly, anemia, elevated lactate dehydrogenase, and elevated alkaline phosphatase. Skin lesions may be the first manifestation of disseminated disease. (See <a class="local">'Clinical features'</a> above and <a class="local">'Laboratory features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Definitive diagnosis of disseminated NTM disease requires recovery of NTM from blood, bone marrow, liver, visceral lymph nodes, or other normally sterile body site. Mycobacterial blood cultures are collected in special media, different from the media used in standard bacterial blood cultures, and must be specifically requested. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of disseminated NTM is usually undertaken in consultation with an expert in infectious diseases. If NTM bacteremia or disseminated disease is associated with a vascular catheter, the catheter must be removed. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest that disseminated NTM disease be treated initially with at least three drugs to which the isolate is susceptible (or likely to be susceptible if susceptibility testing is pending) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Appropriate drugs may include macrolides, <a class="drug drug_pediatric" data-topicid="13286" href="/z/d/drug information/13286.html" rel="external">ethambutol</a>, rifamycins, aminoglycosides, and fluoroquinolones (<a class="graphic graphic_table graphicRef86161" href="/z/d/graphic/86161.html" rel="external">table 2</a>). The initial regimen is continued for one to two months or until there is clinical and radiographic improvement. (See <a class="local">'Antimycobacterial therapy'</a> above and <a class="local">'Initial phase'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The initial treatment phase is followed by a continuation phase. We suggest that during the continuation phase, children with disseminated NTM infection be treated with two drugs to which the isolate is susceptible (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If possible, both of these drugs should be administered orally. The total duration of therapy is 6 to 12 months. (See <a class="local">'Continuation phase'</a> above and <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Survival of disseminated NTM disease is enhanced by immune system recovery (eg, initiation of antiretroviral therapy in HIV-infected children or reduction of immunosuppressive regimen in organ transplant recipients). (See <a class="local">'Outcome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fraser L, Moore P, Kubba H. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. Otolaryngol Head Neck Surg 2008; 138:311.</a></li><li><a class="nounderline abstract_t">Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:905.</a></li><li><a class="nounderline abstract_t">Bolan G, Reingold AL, Carson LA, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis 1985; 152:1013.</a></li><li><a class="nounderline abstract_t">Celdrán A, Esteban J, Mañas J, Granizo JJ. Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair. J Hosp Infect 2007; 66:374.</a></li><li><a class="nounderline abstract_t">Ferguson DD, Gershman K, Jensen B, et al. Mycobacterium goodii infections associated with surgical implants at Colorado hospital. Emerg Infect Dis 2004; 10:1868.</a></li><li><a class="nounderline abstract_t">McNabb A, Eisler D, Adie K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42:3000.</a></li><li><a class="nounderline abstract_t">Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.</a></li><li class="breakAll">Parte AC. List of prokaryotic names with standing in nomenclature. Genus Mycobacterium. Available at: http://www.bacterio.net/mycobacterium.html (Accessed on October 04, 2019).</li><li class="breakAll">American Academy of Pediatrics. Nontuberculous mycobacteria (environmental mycobacteria, mycobacteria other than Mycobacterium tuberculosis). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.814.</li><li><a class="nounderline abstract_t">Cruz AT, Ong LT, Starke JR. Mycobacterial infections in Texas children: a 5-year case series. Pediatr Infect Dis J 2010; 29:772.</a></li><li><a class="nounderline abstract_t">Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 2007; 120:100.</a></li><li><a class="nounderline abstract_t">Fleming GA, Frangoul H, Dermody TS, Halasa N. A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. Pediatr Infect Dis J 2006; 25:567.</a></li><li><a class="nounderline abstract_t">Livni G, Yaniv I, Samra Z, et al. Outbreak of Mycobacterium mucogenicum bacteraemia due to contaminated water supply in a paediatric haematology-oncology department. J Hosp Infect 2008; 70:253.</a></li><li><a class="nounderline abstract_t">Shachor-Meyouhas Y, Sprecher H, Eluk O, et al. An outbreak of Mycobacterium mucogenicum bacteremia in pediatric hematology-oncology patients. Pediatr Infect Dis J 2011; 30:30.</a></li><li><a class="nounderline abstract_t">Al Yazidi LS, Marais BJ, Hazelton B, et al. Nontuberculous Mycobacteria in Children: A Focus on Bloodstream Infections. Pediatr Infect Dis J 2017; 36:374.</a></li><li><a class="nounderline abstract_t">Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954.</a></li><li><a class="nounderline abstract_t">Chesney PJ. Nontuberculous mycobacteria. Pediatr Rev 2002; 23:300.</a></li><li><a class="nounderline abstract_t">Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516.</a></li><li><a class="nounderline abstract_t">Pham-Huy A, Robinson JL, Tapiéro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health 2010; 15:276.</a></li><li><a class="nounderline abstract_t">Vu TT, Daniel SJ, Quach C. Nontuberculous mycobacteria in children: a changing pattern. J Otolaryngol 2005; 34 Suppl 1:S40.</a></li><li><a class="nounderline abstract_t">Ricotta EE, Adjemian J, Blakney RA, et al. Extrapulmonary Nontuberculous Mycobacteria Infections in Hospitalized Patients, United States, 2009-2014. Emerg Infect Dis 2021; 27:845.</a></li><li><a class="nounderline abstract_t">Blyth CC, Best EJ, Jones CA, et al. Nontuberculous mycobacterial infection in children: a prospective national study. Pediatr Infect Dis J 2009; 28:801.</a></li><li><a class="nounderline abstract_t">Horsburgh CR Jr, Caldwell MB, Simonds RJ. Epidemiology of disseminated nontuberculous mycobacterial disease in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1993; 12:219.</a></li><li><a class="nounderline abstract_t">Hoyt L, Oleske J, Holland B, Connor E. Nontuberculous mycobacteria in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1992; 11:354.</a></li><li><a class="nounderline abstract_t">Horsburgh CR Jr, Gettings J, Alexander LN, Lennox JL. Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000. Clin Infect Dis 2001; 33:1938.</a></li><li><a class="nounderline abstract_t">Tumbarello M, Tacconelli E, de Donati KG, et al. Changes in incidence and risk factors of Mycobacterium avium complex infections in patients with AIDS in the era of new antiretroviral therapies. Eur J Clin Microbiol Infect Dis 2001; 20:498.</a></li><li><a class="nounderline abstract_t">Mangione EJ, Huitt G, Lenaway D, et al. Nontuberculous mycobacterial disease following hot tub exposure. Emerg Infect Dis 2001; 7:1039.</a></li><li><a class="nounderline abstract_t">Falkinham JO 3rd. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011; 17:419.</a></li><li><a class="nounderline abstract_t">Stout JE, Gadkowski LB, Rath S, et al. Pedicure-associated rapidly growing mycobacterial infection: an endemic disease. Clin Infect Dis 2011; 53:787.</a></li><li><a class="nounderline abstract_t">Lee WJ, Kim TW, Shur KB, et al. Sporotrichoid dermatosis caused by Mycobacterium abscessus from a public bath. J Dermatol 2000; 27:264.</a></li><li><a class="nounderline abstract_t">von Baum H, Bommer M, Forke A, et al. Is domestic tap water a risk for infections in neutropenic patients? Infection 2010; 38:181.</a></li><li><a class="nounderline abstract_t">Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 2005; 13:7.</a></li><li><a class="nounderline abstract_t">Holland SM. Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity. Immunol Res 2007; 38:342.</a></li><li><a class="nounderline abstract_t">Marazzi MG, Chapgier A, Defilippi AC, et al. Disseminated Mycobacterium scrofulaceum infection in a child with interferon-gamma receptor 1 deficiency. Int J Infect Dis 2010; 14:e167.</a></li><li><a class="nounderline abstract_t">Tsolia MN, Chapgier A, Taprantzi P, et al. Disseminated nontuberculous mycobacterial infection in a child with interferon-gamma receptor 1 deficiency. Eur J Pediatr 2006; 165:458.</a></li><li><a class="nounderline abstract_t">Koscielniak E, de Boer T, Dupuis S, et al. Disseminated Mycobacterium peregrinum infection in a child with complete interferon-gamma receptor-1 deficiency. Pediatr Infect Dis J 2003; 22:378.</a></li><li><a class="nounderline abstract_t">Vesterhus P, Holland SM, Abrahamsen TG, Bjerknes R. Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin Infect Dis 1998; 27:822.</a></li><li><a class="nounderline abstract_t">Boudjemaa S, Dainese L, Héritier S, et al. Disseminated Bacillus Calmette-Guérin Osteomyelitis in Twin Sisters Related to STAT1 Gene Deficiency. Pediatr Dev Pathol 2017; 20:255.</a></li><li><a class="nounderline abstract_t">Haraguchi M, Harada N, Watanabe J, et al. Disseminated nontuberculous mycobacteriosis and fungemia after second delivery in a patient with MonoMAC syndrome/GATA2 mutation: a case report. BMC Infect Dis 2021; 21:502.</a></li><li><a class="nounderline abstract_t">Taur PD, Gowri V, Pandrowala AA, et al. Clinical and Molecular Findings in Mendelian Susceptibility to Mycobacterial Diseases: Experience From India. Front Immunol 2021; 12:631298.</a></li><li><a class="nounderline abstract_t">Aoki A, Sakagami T, Yoshizawa K, et al. Clinical Significance of Interferon-γ Neutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease. Clin Infect Dis 2018; 66:1239.</a></li><li><a class="nounderline abstract_t">Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis 2015; 15:968.</a></li><li><a class="nounderline abstract_t">Wei MC, Banaei N, Yakrus MA, et al. Nontuberculous mycobacteria infections in immunocompromised patients: single institution experience. J Pediatr Hematol Oncol 2009; 31:556.</a></li><li><a class="nounderline abstract_t">Dabaja-Younis H, Damouni-Shalabi R, Ganem-Zoubi N, et al. NonTuberculous Mycobacteria Blood Stream Infection in Pediatric and Adult Patients: 15 Years Surveillance. Pediatr Infect Dis J 2022; 41:e216.</a></li><li><a class="nounderline abstract_t">Nicholson O, Feja K, LaRussa P, et al. Nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplant recipients: case report and review of the literature. Pediatr Infect Dis J 2006; 25:263.</a></li><li><a class="nounderline abstract_t">Lau SK, Curreem SO, Ngan AH, et al. First report of disseminated Mycobacterium skin infections in two liver transplant recipients and rapid diagnosis by hsp65 gene sequencing. J Clin Microbiol 2011; 49:3733.</a></li><li><a class="nounderline abstract_t">Singh S, Yosypiv IV, Iorember FM. Disseminated mycobacterium avium complex infection in a pediatric renal transplant recipient. Clin Pediatr (Phila) 2012; 51:892.</a></li><li><a class="nounderline abstract_t">Longworth SA, Daly JS, AST Infectious Diseases Community of Practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13588.</a></li><li><a class="nounderline abstract_t">Shachor-Meyouhas Y, Geffen Y, Arad-Cohen N, et al. Mycobacterium phocaicum bacteremia: an emerging infection in pediatric hematology-oncology patients. Pediatr Infect Dis J 2014; 33:1299.</a></li><li><a class="nounderline abstract_t">Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</a></li><li><a class="nounderline abstract_t">Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin Microbiol Infect 2009; 15:906.</a></li><li><a class="nounderline abstract_t">Friedman BF, Edwards D, Kirkpatrick CH. Mycobacterium avium-intracellulare: cutaneous presentations of disseminated disease. Am J Med 1988; 85:257.</a></li><li class="breakAll">Department of Health and Human Services. Panel on opportunistic infections in HIV-exposed and HIV-infected children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Mycobacterium avium complex disease. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/mycobacterium-avium-complex-disease (Accessed on June 16, 2021).</li><li class="breakAll">Tebruegge M, Curtis N. Mycobacterium nontuberculosis species. In: Principles and Practice of Pediatric Infectious Diseases, 5th ed, Long SS, Prober CG, Fischer M (Eds), Elsevier, Philadelphia 2018. p.806.</li><li><a class="nounderline abstract_t">Gordin FM, Cohn DL, Sullam PM, et al. Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J Infect Dis 1997; 176:126.</a></li><li><a class="nounderline abstract_t">Parent LJ, Salam MM, Appelbaum PC, Dossett JH. Disseminated Mycobacterium marinum infection and bacteremia in a child with severe combined immunodeficiency. Clin Infect Dis 1995; 21:1325.</a></li><li><a class="nounderline abstract_t">Hanke CW, Temofeew RK, Slama SL. Mycobacterium kansasii infection with multiple cutaneous lesions. J Am Acad Dermatol 1987; 16:1122.</a></li><li><a class="nounderline abstract_t">Pacios E, Alcalá L, Ruiz-Serrano MJ, et al. Evaluation of bone marrow and blood cultures for the recovery of mycobacteria in the diagnosis of disseminated mycobacterial infections. Clin Microbiol Infect 2004; 10:734.</a></li><li><a class="nounderline abstract_t">Rose PC, Schaaf HS, Marais BJ, et al. Value of bone marrow biopsy in children with suspected disseminated mycobacterial disease. Int J Tuberc Lung Dis 2011; 15:200.</a></li><li><a class="nounderline abstract_t">Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139:4.</a></li><li><a class="nounderline abstract_t">Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J 2019; 54.</a></li><li><a class="nounderline abstract_t">Chong C, Sinclair J, Voss L, et al. Ophthalmic manifestation of disseminated cutaneous Mycobacterium avium-intracellulare complex in a child with a presumed primary IL-12 receptor defect. Ocul Immunol Inflamm 2015; 23:106.</a></li><li><a class="nounderline abstract_t">Lai CC, Lee LN, Ding LW, et al. Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan. J Infect 2006; 53:77.</a></li><li><a class="nounderline abstract_t">Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.</a></li><li><a class="nounderline abstract_t">Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 173:1283.</a></li><li><a class="nounderline abstract_t">Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999; 28:1080.</a></li><li><a class="nounderline abstract_t">Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:1234.</a></li><li><a class="nounderline abstract_t">Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121:905.</a></li><li><a class="nounderline abstract_t">Sullam PM, Gordin FM, Wynne BA. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group. Clin Infect Dis 1994; 19:84.</a></li><li><a class="nounderline abstract_t">Magis-Escurra C, Alffenaar JW, Hoefnagels I, et al. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. Int J Antimicrob Agents 2013; 42:256.</a></li><li><a class="nounderline abstract_t">Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42:631.</a></li><li><a class="nounderline abstract_t">Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186:917.</a></li><li><a class="nounderline abstract_t">Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrob Agents Chemother 2016; 60:2171.</a></li><li class="breakAll">Ethambutol efficacy and toxicity: Literature review and recommendations for daily and intermittent dosage in children. World Health Organization, 2006. Available at: https://apps.who.int/iris/bitstream/handle/10665/69366/WHO_HTM_TB_2006.365_eng.pdf?sequence=1&amp;isAllowed=y.</li><li class="breakAll">World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children (2014) https://www.who.int/tb/publications/childtb_guidelines/en/ (Accessed on May 29, 2021).</li><li><a class="nounderline abstract_t">Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361.</a></li><li><a class="nounderline abstract_t">Puthanakit T, Oberdorfer P, Ukarapol N, et al. Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection. Pediatr Infect Dis J 2006; 25:645.</a></li><li><a class="nounderline abstract_t">Wang ME, Castillo ME, Montano SM, Zunt JR. Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J 2009; 28:900.</a></li><li><a class="nounderline abstract_t">Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554.</a></li><li><a class="nounderline abstract_t">Bax HI, Freeman AF, Ding L, et al. Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol 2013; 33:991.</a></li><li><a class="nounderline abstract_t">Havlir DV, Dubé MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392.</a></li><li><a class="nounderline abstract_t">Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181:1289.</a></li><li class="breakAll">American Academy of Pediatrics. Tuberculosis. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.786.</li><li><a class="nounderline abstract_t">Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329:828.</a></li><li><a class="nounderline abstract_t">Unal E, Yen C, Saiman L, et al. A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2006; 12:1188.</a></li><li><a class="nounderline abstract_t">Zaidi S, Elidemir O, Heinle JS, et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11:243.</a></li></ol></div><div id="topicVersionRevision">Topic 14425 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312877" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32797222" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4045242" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655974" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504281" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mycobacterium goodii infections associated with surgical implants at Colorado hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243051" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692101" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692101" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692101" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20661106" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mycobacterial infections in Texas children: a 5-year case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606567" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16732163" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799238" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outbreak of Mycobacterium mucogenicum bacteraemia due to contaminated water supply in a paediatric haematology-oncology department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20651636" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An outbreak of Mycobacterium mucogenicum bacteremia in pediatric hematology-oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918379" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nontuberculous Mycobacteria in Children: A Focus on Bloodstream Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795100" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12205297" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nontuberculous mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7618936" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21532791" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16089239" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nontuberculous mycobacteria in children: a changing pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33622461" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Extrapulmonary Nontuberculous Mycobacteria Infections in Hospitalized Patients, United States, 2009-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636280" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nontuberculous mycobacterial infection in children: a prospective national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095716" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Epidemiology of disseminated nontuberculous mycobacterial disease in children with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1630855" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nontuberculous mycobacteria in children with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692307" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561808" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Changes in incidence and risk factors of Mycobacterium avium complex infections in patients with AIDS in the era of new antiretroviral therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11747738" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nontuberculous mycobacterial disease following hot tub exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21392432" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21921222" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pedicure-associated rapidly growing mycobacterial infection: an endemic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10824491" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sporotrichoid dermatosis caused by Mycobacterium abscessus from a public bath.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237946" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Is domestic tap water a risk for infections in neutropenic patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15639625" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Biofilm formation and dispersal and the transmission of human pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917041" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880337" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Disseminated Mycobacterium scrofulaceum infection in a child with interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16602008" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Disseminated nontuberculous mycobacterial infection in a child with interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712974" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Disseminated Mycobacterium peregrinum infection in a child with complete interferon-gamma receptor-1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9798040" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Familial disseminated infection due to atypical mycobacteria with childhood onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28521627" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Disseminated Bacillus Calmette-Guérin Osteomyelitis in Twin Sisters Related to STAT1 Gene Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34051752" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Disseminated nontuberculous mycobacteriosis and fungemia after second delivery in a patient with MonoMAC syndrome/GATA2 mutation: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33732252" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical and Molecular Findings in Mendelian Susceptibility to Mycobacterial Diseases: Experience From India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29126235" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical Significance of Interferon-γNeutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26049967" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Host susceptibility to non-tuberculous mycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19641470" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nontuberculous mycobacteria infections in immunocompromised patients: single institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35093997" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : NonTuberculous Mycobacteria Blood Stream Infection in Pediatric and Adult Patients: 15 Years Surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511393" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplant recipients: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880973" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : First report of disseminated Mycobacterium skin infections in two liver transplant recipients and rapid diagnosis by hsp65 gene sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21669902" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Disseminated mycobacterium avium complex infection in a pediatric renal transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077618" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037036" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mycobacterium phocaicum bacteremia: an emerging infection in pediatric hematology-oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277290" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845702" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical manifestations of nontuberculous mycobacteria infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3400704" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mycobacterium avium-intracellulare: cutaneous presentations of disseminated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3400704" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mycobacterium avium-intracellulare: cutaneous presentations of disseminated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3400704" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mycobacterium avium-intracellulare: cutaneous presentations of disseminated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207358" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589169" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Disseminated Mycobacterium marinum infection and bacteremia in a child with severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3584591" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mycobacterium kansasii infection with multiple cutaneous lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301676" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Evaluation of bone marrow and blood cultures for the recovery of mycobacteria in the diagnosis of disseminated mycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21219681" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Value of bone marrow biopsy in children with suspected disseminated mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912355" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30880280" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24884801" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ophthalmic manifestation of disseminated cutaneous Mycobacterium avium-intracellulare complex in a child with a presumed primary IL-12 receptor defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16313964" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19489710" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16514112" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452638" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557969" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978715" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7948562" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23837923" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9517944" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22878281" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26810651" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26810651" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26810651" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919622" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16804438" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687769" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804191" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23512243" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Interferon alpha treatment of patients with impaired interferon gamma signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8676932" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10762562" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10762562" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179648" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085312" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19298240" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
